Navigation Links
RSB Spine, LLC, Announces Distribution Agreement with Paradigm BioDevices, Inc.

CLEVELAND, Sept. 30 /PRNewswire/ -- RSB Spine, LLC, today announced that it has signed an exclusive master distribution agreement with Paradigm BioDevices, Inc. for the U.S. market. Paradigm BioDevices was instrumental in developing the Stand Alone 360 market for ZERO-Profile(SM) ALIF implants, which is one of the fastest growing segments in the spine market. RSB Spine's growing portfolio of modular fusion products offers surgeons more choices than existing technologies in the zero profile segment of the market. Moreover, RSB Spine will introduce two new products this year, and two additional products in 2010, making the need for effective distribution critical to the ongoing success of the company.

RSB Spine Chief Executive Officer John A. Redmond said: "We are delighted with this partnership and believe that Paradigm BioDevices' proven success and expertise in this market will greatly enhance our efforts to bring unique, surgeon-friendly implants to RSB's customers. Distribution is one of the most difficult aspects of this business, and we are confident that Paradigm BioDevices will provide increased opportunities for access to quality agents and rapid sales growth."

Paradigm BioDevices, Inc., Chief Executive Officer Mike O'Neill said: "RSB's product portfolio is a truly innovative and remarkable platform that offers surgeons the ability to select material and mechanical properties that best meet their patients' individual needs. We are excited to be involved with RSB's unique products and the diverse market opportunity they afford."

RSB Spine is a privately held medical device company focused on developing innovative spinal implants with a focus on modular fusion products.

Paradigm BioDevices is a privately held manufacturer and distributor of minimally invasive tissue collection systems and novel spinal implant technologies. The company, founded in 1997, is based in Boston and has a U.S. distribution network of 68 agents and more than 250 representatives.


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:11/25/2015)... Research and Markets ( ) has ... Global Forecast to 2020" report to their offering. ... 37.21% of the total market share in 2014. The ... is projected to growth at the highest CAGR between ... to the fast growing water, industrial gas treatment, pharmaceutical, ...
(Date:11/25/2015)... , Frankreich, November 25, 2015 ... bekanntgegeben, dass sie eine Lizenz für das Patent über ... CNRS, UCBL und ENS-Lyon innehaben, an Enyo Pharma vergeben ... FUI AAP8 ins Leben gerufenen und von Edelris gemeinsam ... FXR als ein Behandlungsziel für HBV identifiziert, und es ...
(Date:11/25/2015)... November 25, 2015 ... addition of the  "Global Drug Device ... to their offering.  --> ... of the  "Global Drug Device Combination ... their offering.  --> Research ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... Since its launch in 2012, the ... stem cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. ... Trademark (RTM). , Organizations are required to hold a registered trademark in order ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Students and ... were awarded to winners of the Create Real Impact awards. California Casualty ... to help stem the tide of distracted and reckless driving, the number one killer ...
(Date:11/25/2015)... ... 25, 2015 , ... Bunion Bootie , the newest ... of the early holiday shopping season. Starting Wednesday November 25th, Bunion Booties are ... Friday promotional pricing is in addition to any automatic discounts applied when buying ...
(Date:11/24/2015)... , ... November 25, 2015 , ... ... monitoring. Their Care Plan software creates an agreement between the practice owner ... plan, including financial, scheduling, monitoring, notification, and projections. Click here ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, ... many benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser ... used by a dentist in Gettysburg, PA . From routine visits to ...
Breaking Medicine News(10 mins):